24th June 2021
42 startups from across Europe with 6 based in Ireland-UK have been selected for the EIT Health Catapult semi-finals.
The start-ups will receive intensive training from experts, meet investors and corporates, and compete in pitch contests to progress to the finals.
The EIT Health Catapult, currently in its sixth year, is a training and competition programme that boosts the development of European health start-ups by exposing them to top quality experts and international investors. The programme has already supported over 189 start-ups and has seen the participation of over 2500 healthcare professionals.
The start-ups chosen for the Semi-finals will now enter intense training days, during which they will be teamed up with mentors. The mentors review and potentially optimise the company business plan, and provide thorough pitch training, in order to improve the start-up’s ability to perform a funding roadshow in front of top-level seed or A-series investors.
After the training, semi-finalists will pitch in front of an international, high-profile jury and an audience of experienced corporate representatives, experts and investors. The top companies in the three categories of biotech, medtech and digital health – 21 start-ups in total – will be selected and invited to pitch during the finals at the EIT Health Summit. They will go head-to-head for their share of the €210,000 investment prize fund with the Audience Award Winner displayed on the New York Nasdaq Tower.
The Ireland-UK selected start-ups are:
Renovos Biologics (Ireland-UK) is transforming regenerative medicine and orthopaedics through pioneering use of Renovite nanoclay gels from world-class stem cell research.
SolasCure’s (Ireland-UK) proprietary technology leverages biomimicry and evidence-based medicine to treat patients with chronic wounds.
FeelTect (Ireland-UK) delivers connected-health technology for measuring and monitoring wound treatments, enabling data-driven optimisation of care.
Luminate Medical (Ireland-UK) is developing a novel technology to prevent chemotherapy induced hair loss in a portable, comfortable and patient-focused way.
Brightlobe (Ireland-UK) has invented cutting-edge technology that can both assess and
support paediatric neurodevelopment using clinically-validated mobile games.
Amara Therapeutics (Ireland-UK) have developed RiSolve, a “software as drug” digital platform that treats Overactive Bladder (OAB) more effectively and safely than current prescribed medication.
Watch the Semi-finals online
The EIT Health Catapult is inviting investors and experts to attend the virtual Semi-finals, from 1-3 December 2021, for the pitches and for matchmaking. These events provide the opportunity to make early contacts with the healthcare leaders of tomorrow. Find out more and register.
Dates for the public pitch days of the semi-finals are:
Biotech: 1 December 2021
Medtech: 2 December 2021
Digital Health: 3 December 2021
Ochre Bio closes €30M Series A funding round
Learn more about their development
NALA.care joins forces with La Roche-Posay
Discover how the partnership will benefit patients
Leuko closes €5M Series A round
Learn more about Leuko and its achievements